Astrazeneca PLC (AZN)

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps.

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients.

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps.

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio.

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile.

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer.